High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tarhini, Ahmad A.
Kirkwood, John M.
Tawbi, Hussein A.
Funding for this research was provided by:
National Cancer Institute (US) (P50 CA121973)